ARTICLE | Clinical News
Inclisiran: Ph II ORION-2 started
February 1, 2017 9:45 PM UTC
The Medicines Co. began the open-label, Dutch Phase II ORION-2 trial to evaluate 300 mg subcutaneous inclisiran in about 10 patients. Patients whose mean serum PCSK9 levels are not suppressed by >70%...
BCIQ Target Profiles